Back to top
more

Novartis (NVS)

(Real Time Quote from BATS)

$113.85 USD

113.85
75,481

-0.01 (-0.01%)

Updated Oct 8, 2024 10:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance

by Zacks Equity Research

Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.

Sweta Killa headshot

Biotech Leading in Q4: Best ETFs & Stocks

by Sweta Killa

We highlight five biotech ETFs and stocks that are leading the market in Q4.

Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy

by Zacks Equity Research

Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.

Kinjel Shah headshot

Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs

by Kinjel Shah

Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.

AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU

by Zacks Equity Research

AbbVie's (ABBV) oral JAK inhibitor, upadacitinib, receives approval in Europe for treating rheumatoid arthritis under the trade name of Rinvoq.

Novartis' Asthma Candidate Fails in LUSTER Phase III Studies

by Zacks Equity Research

Novartis' (NVS) asthma candidate, fevipiprant, fails to meet endpoint in the phase III LUSTER studies.

Novartis Gets Positive CHMP Opinion for Wet AMD Drug Beovu

by Zacks Equity Research

Novartis (NVS) obtains positive CHMP opinion for its wet AMD drug Beovu. A potential approval will boost its ophthalmology franchise.

Novartis (NVS) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Novartis (NVS) closed the most recent trading day at $93.06, moving +0.02% from the previous trading session.

The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America

Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy

by Zacks Equity Research

Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.

Roche's (RHHBY) sBLA for Asthma Drug Xolair Accepted by FDA

by Zacks Equity Research

The FDA accepts Roche's (RHHBY) allergic asthma drug Xolair's sBLA for the treatment of nasal polyps in adult patients aged 18 years or above with inadequate response to intranasal corticosteroids.

Mark Vickery headshot

Top Research Reports for Novartis, AbbVie & Sanofi

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), AbbVie (ABBV) and Sanofi (SNY).

Neena Mishra headshot

Why Biotech ETFs are Surging to New Highs

by Neena Mishra

increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research

by Zacks Equity Research

Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.

Gilead (GILD) Announces Positive Long-Term Data on Yescarta

by Zacks Equity Research

Gilead (GILD) announces positive long-term data from a mid-stage study on Yescarta in adult patients with refractory large B-cell lymphoma.

Biogen Up on New Data on Alzheimer's Candidate Aducanumab

by Zacks Equity Research

Biogen (BIIB) divulges new positive data on Alzheimer's candidate, aducanumab at CTAD. Stock rises.

Regeneron Reports Positive Data on Rare Blood Disorder Drug

by Zacks Equity Research

Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.

Novartis (NVS) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Novartis (NVS) closed at $91.64 in the latest trading session, marking a +0.09% move from the prior day.

Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up

by Zacks Equity Research

Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.

Biogen's Shares Down on Rating Downgrade by Baird Analyst

by Zacks Equity Research

Biogen's (BIIB) shares decline following a rating downgrade by an analyst at Robert W. Baird on concerns related to approval of Alzheimer's disease candidate, aducanumab.

Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space

by Zacks Equity Research

Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.

Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD

by Zacks Equity Research

Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.

Sweta Jaiswal, FRM headshot

Why Biotech ETFs Surged in Monday's Trading Session

by Sweta Jaiswal, FRM

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to drive the biotech market.

Kinjel Shah headshot

4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal

by Kinjel Shah

Here are four stocks that boast promising prospects and are most likely to be takeout targets.

Roche's NDA for SMA Drug Risdiplam Gets Priority Review

by Zacks Equity Research

The FDA accepts Roche's (RHHBY) NDA for risdiplam under a priority review to treat spinal muscular atrophy. A verdict is pending on May 24, 2020.